AbbVie Inc. has a multi-modality migraine drug franchise, now expanded with a broader US label for its oral CGRP inhibitor Qulipta (atogepant) in migraine prevention, but the company is facing tough competition in the anti-CGRP space, which recently added yet another approved product with a first-in-class route of administration.
Qulipta won US Food and Drug Administration approval for the prevention of episodic migraine (14 headaches or fewer per month)...






